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ImmunohistochemistrySummary Vascular involvement is frequent in systemic sclerosis, but the role of the lymphatic
vasculature is poorly known. Our aim was to evaluate lymphatic vessels in systemic sclerosis skin
lesions. We studied skin forearm biopsies of 9 patients with systemic sclerosis and 7 age-matched
controls. Lymphatic vessels were labeled with the monoclonal antibody D2-40 and blood vessels with a
polyclonal antibody to von Willebrand Factor. All blood and lymphatic vessels present in each section
were counted and total area, inner luminal area, and shape factors were measured. The number of blood
and lymphatic vessels in papillary dermis was greater and their diameter lower than in reticular dermis
both in systemic sclerosis and controls. In the reticular dermis, the number of lymphatic vessels was
markedly reduced in systemic sclerosis (4.9 ± 1.1 μm−2 versus 8.9 ± 1.2 μm−2 P = .03), and a similar
trend was observed in papillary dermis (8.4 ± 3.7 μm−2 versus 8.1 ± 5.3 μm−2). Interestingly, the
number of periglandular lymphatics in systemic sclerosis was not different from controls. The inner
luminal area (possibly indicating compensatory dilation) of lymphatic vessels, particularly the
periglandular ones, was greater in systemic sclerosis than in controls. No differences were observed in
the number of blood vessels, but the percentage of blood vessel profiles (without lumen) was
significantly less in systemic sclerosis both in papillary and in reticular dermis. In conclusion, our data
show that skin lesions in systemic sclerosis are characterized by a selective rarefaction of lymphatic
vasculature that spares periglandular vessels and that might have a pathogenic role in the evolution and
in the clinical manifestations of the disease.
© 2010 Elsevier Inc. Open access under CC BY-NC-ND license. Abbreviations: SSc, systemic sclerosis; vWF, von Willebrand Factor;
EGF, Vascular Endothelial Growth Factor.
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Open access under CC BY-NC-ND license. 1. IntroductionScleroderma or Systemic Sclerosis (SSc) is an autoim-
mune connective tissue disease of unknown etiology
characterized by abnormalities of vasculature, immune
367Lymphatic and blood vessels in scleroderma skinsystem, and extracellular matrix that lead to fibrosis of the
skin and internal organs (lungs, gastrointestinal tract, heart,
and kidneys) [1,2].
Vascular injury and endothelial activation are among the
earliest and potentially primary events in the pathogenesis of
SSc [3-5]. The first symptom is Raynaud's phenomenon
(RP), an episodic and reversible vasospasm of the fingers and
toes. Under normal conditions or in primary (idiopathic) RP,
nailfold capillaroscopy shows a regular disposition of the
capillary loops along the nail bed whereas in secondary RP
there are numerous capillaroscopic abnormalities, suggesting
the presence of a connective tissue disease [6]. In the skin of
SSc patients, nail fold videocapillaroscopy shows progres-
sive changes in the capillary network [7] with the
advancement of disease. At the early stages, capillary
distribution is well preserved with few enlarged/giant
capillaries and few capillary hemorrhages that become
subsequently more frequent, with a mild disorganization of
the capillary architecture and the presence of edema. The
“late” nail fold video-capillaroscopy pattern is characterized
by irregular capillary enlargement, hemorrhages, severe loss
of capillaries with extensive avascular areas, disorganization
of the normal capillary array, and appearance of ramified/
bushy capillaries.
The abnormal function of the endothelium leads to
edema, leukocyte and platelet adhesion, and perivascular
inflammation. The earliest signs of fibrosis appear in the
areas where vascular perturbation is most severe [4].
More recently, a reduction in capillary density has also
been observed in forearm skin biopsies of SSc patients.
Interestingly, the changes appeared to involve mostly
capillaries without a visible lumen (“profiles”) and to be
reversed by stem cell therapy [1].
The characteristic reduction of capillary density in SSc
skin suggests a deregulated, insufficient angiogenic
response. The term angiogenesis describes a complex
process that leads to the formation of new vessels by
sprouting of differentiated endothelial cells from pre-
existing ones. In the skin of SSc patients, angiogenesis is
insufficient despite severe hypoxia [8], a well-known major
proangiogenic stimulus. Vascular endothelial growth factor
(VEGF), a regulatory factor involved in several steps of
physiological and pathological angiogenesis, is strongly
overexpressed in the skin and serum of SSc patients [9]
and serum levels of VEGF correlate with the development
of fingertip ulcers [10]. Overexpression of VEGF occurring
over a limited time has been shown to induce the formation
of new functional vessels in adult organs. Prolonged
exposure to VEGF leads, however, to formation of a
chaotic vessel network with megacapillaries and reduced
blood flow, resembling the disturbed vessel morphology of
SSc patients [11]. Another vascular disorder, possibly
related to growth factor stimulation of blood vessels,
telangiectasias, is frequently seen in the limited form of
SSc, most commonly on the face but also on the hand and
internally [12].Lymphatic vessels are also extensively present in the skin
and are known to participate in a variety of physiological and
pathological processes that could be relevant in SSc,
including lymphoedema, wound healing, and inflammatory
reactions [13-15]. The investigation of lymphatic vessels has
been long hampered by the difficulty in their identification
and distinction from blood vessels, particularly venules.
Moreover, when lymphatics are not filled with lymph, they
tend to collapse and may become impossible to recognize.
The recent discovery of D2-40 [16], a monoclonal antibody
to podoplanin [17], that consistently and specifically reacts
with lymphatic endothelium, has made histological study of
lymphatic vessels feasible. In the present study we evaluated
the distribution and morphology of lymphatic vessels stained
with D2-40 and blood vessels stained with von Willebrand
Factor (vWF) in the forearm affected skin of SSc patients
compared to controls. The aim was to understand why SSc
patients have no clinical evidence of lymphoedema in spite
of the profound alterations of their skin that might potentially
affect lymphatic circulation. We wondered whether lym-
phatic vessels might be increased in number as in
inflammation [14,18] and wound healing [19], decreased in
number due to inhibition of lymphangiogenesis by trans-
forming growth factor beta1 overexpression [20,21], which
is a hallmark of fibrotic diseases [2] and/or dilated as in
conditions of chronic lymphostasis [13].
To the best of our knowledge, the only report on
lymphatic vessels in the skin of SSc patients is a fluorescence
microlymphography study by Leu et al. [22]. A solution of
fluorescein isothiocyanate-dextran was injected into the
subepidermal layer of the skin of fingers, hands and
forearms. Lymphatic capillaries became visible in healthy
controls. In SSc patients, the clinically affected areas showed
a pattern of lymphatic microangiopathy, already described in
lymphoedema and chronic venous insufficiency, character-
ized by increased length of the visualized lymphatic
capillaries and cutaneous backflow or even the complete
absence of stained microlymphatics. There was a correlation
between disease duration and complete disappearance of the
lymphatic network. Despite this evidence, to date, there are
no histologic studies on lymphatic vessels in SSc.2. Materials and methods
2.1. Patients
Biopsies of affected skin were obtained with informed
consent, and ethical approval (RFH Ethics Committee), from
the forearms of 9 patients affected by SSc classified
according to LeRoy [23], of which 5 had limited and 4 had
diffuse SSc (Table 1). No further information was available
for one of the patients with the limited form, who was
referred from another institution. Three patients had
relatively early disease (b2 years), 5 had long standing
Table 1 Patients characteristics. Skin score was assessed with
the modified Rodnan's skin score
SSc (9) Limited
SSc (5)
Diffuse
SSc (4)
Age 51.5 ± 4.3 a 58 ± 5 a 45.2 ± 6 a
Disease duration 10 ± 3 a 9.2 ± 5 a 11 ± 5 a
Skin score 13.1 ± 4 a 13.7 ± 6.5 a 12.5 ± 5.7 a
Fingertip ulcers 1 1 0
Autoantibodies
ANA+ b 6 3 3
RNAP+ c 1 0 1
Scl-70+ d 5 4 3
DLCO (%)
e 46.6 ± 12.8 a 59.5 ± 22.4 a 33.7 ± 11.7 a
PAH f 1 0 1
a mean ± SEM.
b ANAs, antinuclear antibodies.
c RNAP, anti-RNA-polymerase antibodies.
d Scl-70, anti- Scl-70 autoantibodies (anti-topoisomerase I).
e DLCO, carbon monoxide diffusion capacity.
f PAH, pulmonary hypertension.
368 A. Rossi et al.disease (N10 years), and 1 had an intermediate disease length
of 4 years. Clinical assessment of patients is summarized in
Table 2. Site-matched normal skin samples were obtained
from 7 sex- and age-matched volunteers.
2.2. Immunohistochemistry
All samples were fixed in 10% formalin and embedded in
paraffin. Before immunohistochemical labeling, sections
were rehydrated via xylene and ethanol and placed for 10
minutes in boiling Antigen Unmasking Solution (VECTOR
Laboratories, Burlingame, CA) for antigen retrieval. Endog-
enous peroxidase activity was quenched with 3% H2O2 for
15 minutes in the dark, and unspecific binding sites were
blocked for 30 minutes with phosphate buffered saline
containing 3% bovine serum albumin. Double labeling was
performed by the sequential use of the monoclonal antibody
D2-40 (Signet) that specifically stains lymphatic vessels [16]Table 2 Clinical characteristics of SSc patients
Limited
SSc (5)
Diffuse
SSc (4)
Mean duration of Raynaud's
at time of biopsy
11 years
9 months
3 years
8 months
Muscle involvement No 1 polymyositis
Joint involvement 2 No
Renal involvement No No
Heart involvement No No
Lung involvement 2 pulmonary
fibrosis
4 pulmonary
fibrosis
(1 minimal)
Edema in forearms 2 2
Teleangectasias 3 4and a polyclonal antibody to vWF (DakoCytomation,
Glostrup, Denmark), expressed by blood endothelium and,
to a lesser extent, by lymphatic endothelium. Lymphatic
vessels were stained by incubating sections for two hours at
room temperature with D2-40 diluted 1:40 in phosphate-
buffered saline containing 0.5% bovine serum albumin
(hereafter referred to as buffer), followed by 30-minute
incubation with antimouse IgG (Dako) diluted 1:25 in buffer
and, eventually, 30 minutes with peroxidase-antiperoxidase
(PAP-mouse, Dako) diluted 1:100 at room temperature. The
reaction was revealed with 3,3′-diaminobenzidine Substrate
Kit for Peroxidase (VECTOR), which contains a nickel
solution that converts the brown color characteristic of 3,3′-
diaminobenzidine in black. Lymphatic vessels were rendered
easily recognizable by their black staining that was not
covered by the subsequent red staining with the polyclonal
antibody to vWF. Blood vessels were then stained by
overnight incubation at 4°C with the polyclonal antibody to
vWF (1:50) followed by a 45-minute incubation at room
temperature with anti-rabbit/alkaline phosphatase (Dako)Fig. 1 Consecutive sections of human control skin stained with
two different lymphatic markers: the endothelium of the two
lymphatic vessels indicated by arrows is intensely and completely
stained by D2-40 (A), faintly and incompletely stained by LYVE–1
(B). Original magnification ×20.
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Chromogen System (Dako) so that blood vessels were
stained in red. Sections were counterstained with hematox-
ylin. In preliminary experiments aimed at selecting the most
reliable lymphatic marker, the same vessels that stained
strongly with D2-40 (Fig. 1A) were stained, not completely
and less intensely by LYVE-1 (Lifespan Biosciences,
Seattle, WA, 1:20) (Fig. 1B). D2-40 was thereafter used as
lymphatic marker.
Some sections were also stained with a polyclonal
antibody to VEGF-C (Invitrogen, diluted 1:50 in buffer)
followed by an alkaline phosphatase conjugated goat
antirabbit secondary antibody (Dako, diluted 1:50 in
buffer). The reaction was revealed by BCIP/NBT Substrate
System (Dako).
Samples were viewed under a Nikon Eclipse E600 light
microscope equippedwith a digital camera. The entire section
was photographed with 4× and 20× magnification objective.
2.3. Morphometric analysis
The area of papillary and reticular dermis was obtained
from the total section area computed with a 4× objective after
subtracting the area occupied by hypodermic fat and
sebaceous glands. The whole area of each section was then
examined with a 20× objective and all the lymphatic (stained
in black byD2-40), and blood (stained in red by vWF) vessels
in each section were counted. Total area, outer perimeter and
inner luminal area were measured using the morphometric
software “Nis Elements” by Nikon. Inner luminal area was
automatically calculated by the software tracing the inner
luminal profile and was expressed as a percentage of total
vessel area measured tracing the outer profile of the vessel.
Roundness factor was computed as (4π area)/perimeter2, and
ellipse shape factor, as the ratio between the shorter and the
longer radium of an ellipse having the same area and
perimeter of each vessel. Both parameters can have a
maximum value of 1 in the case of a perfectly circular
vessel, with decreasing values as the shape of the vessel
departs from circularity. Vessel density was expressed as the
total number of vessels identified in each patient divided by
the tissue area in mm2, and vessel area, as the percentage of
the sum of the areas of all vessels over tissue area.
2.4. Statistical analysis
Vessel density and areas were compared using Student t
test. Mean vessel area, percentage of inner luminal area,
roundness, and ellipse shape factor were compared using
linear mixed models with diagnosis (control or SSc), layer
(papillary or reticular), and their interaction as fixed effects
and the patient as random effects. Changes in the percentage
of vessels with or without a visible lumen (profiles) were
analyzed using similar logistic generalized mixed models.
Mean estimates were obtained in the appropriate subsamples
as the intercept and SE of the constant for fixed effect inmodels where no factors with fixed effects were included.
Unless otherwise specified, data are presented as M ± SE. A
value of P b .05 for a two-tail distribution was considered
significant. All the analyses were performed using R version
2.8.1, http://www.r-project.org [24].3. Results
3.1. General morphology
Under light microscopy, as expected, there were many
tissue changes between the skin of SSc patients and controls:
altered thickness of the epidermis, loss of dermal-epidermal
ridges, and flattening of papillae (Fig. 2). These modifica-
tions became more severe with duration of disease. The
epidermis of SSc patients with a duration of disease of more
than 2 years had a mean thickness of 65.2 ± 6.7 μm (mean ±
SE) versus 49.0 ± 4.0 μm of early SSc (first 2 years of
disease) and 42.6 ± 3.4 μm of controls (P b .05). All the 3
patients with a duration of disease lower than 2 years had
forearm edema. Forearm edema was also present in 1 of the 5
patients with a long duration of disease (23 years). Sebaceous
and sweat glands and hair follicles appeared to be preserved
also in SSc patients.
3.2. Immunohistochemistry
Lymphatic vessels were consistently and intensely stained
by D2-40. Cross-reactivity, even if of lower intensity, was
only found in some epithelial cells particularly in the basal
layer of sebaceous glands. No reactivity was ever found in
blood vessels. Most of the lymphatic vessels had a patent
lumen delineated by a tortuous and irregular profile (Fig.
1A). Their wall was made solely by endothelial cells which
were stained in dark brown by the immunohistochemical
reaction. Some lymphatic vessels were completely or
partially collapsed. As to blood vessels, the endothelium
and the subendothelial layer were stained in red by vWF
(Fig. 2). The reaction was particularly pronounced in smaller
vessels (capillaries and venules).
3.3. Morphometric evaluation
No differences were observed between sections from
controls and SSc patients in the mean area of papillary
dermis (0.15 ± 0.01 versus 0.16 ± 0.3 mm2) or of reticular
dermis tissue (1.8 ± 0.2 versus 2.5 ± 0.6 mm2) present in each
section. A total of 1365 blood vessels (527 in controls and
838 in SSc) and 215 lymphatic vessels (111 in controls and
104 in SSc) were identified and measured.
Both in controls and SSc biopsies, the density of
lymphatic and blood vessels in the papillary dermis resulted
markedly greater, and their mean area conversely smaller,
than in the reticular dermis (Table 3 and Fig. 2).
Fig. 2 Double staining of lymphatic vessels with D2-40 (arrows) and blood vessels (arrowheads) with vWF in the papillary (A and B) and
reticular (C and D) dermis of controls (A and C) and SSc patients (B and D). In SSc affected skin (B) papillae are flattened and the epidermis is
thicker. Original magnification ×20.
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area was significantly lower than in controls in the reticular
dermis, and a similar trend (although not reaching statistical
significance) was observed in the papillary layer. Further-
more, although the mean outer area was similar in the two
groups (Table 3 and Fig. 3), in the reticular dermis the
percentage of inner luminal area, which can be considered a
sign of dilation (Table 3 and Fig. 4), was significantly greater
in SSc with respect to controls (P b .05). This difference was
mainly due to the dilation of periglandular lymphatics. As to
profiles (vessels without visible lumen) there was no
difference in lymphatic profiles number in SSc skin
compared to controls (Table 3), whereas there was a
significant (P b .05) reduction of blood profiles in SSc
versus controls.
No differences were observed between the two groups
in the density, total and mean area or inner luminal area of
blood vessels either in the papillary or in the reticular
dermis. However, the percentage of blood vessels without a
visible lumen was significantly lower in SSc than in
controls (P b .05), both in the papillary and in the reticular
dermis (Table 3).As expected, blood vessels showed a higher degree of
circularity with respect to lymphatic vessels according to
both the morphological form factors investigated. However,
no statistical differences in these form factors were observed
between the two groups. No statistical effects were observed
when the age of patients and duration of disease were added
to the statistical models.
Because while scoring we had the impression that
lymphatic vessels in connection with glands were relatively
preserved in patients with SSc with respect to controls (Fig.
5A and B), we conducted a post hoc analysis comparing
the density of lymphatic vessels connected or not
connected with glands (b100 μm from the closest
sebaceous or sweat gland). No differences were observed
between the two groups in the area occupied by sebaceous
glands or the density of sweat glands. The density of
lymphatic vessels not connected to glands was reduced in
SSc with respect to controls (3.9. ± 1.0 versus 8.6 ±
1.4 mm−2, P = .02), whereas an opposite trend, without a
significant difference, was observed among lymphatic
vessels close to glands (0.3 ± 0.3 versus 1.0 ±
0.3 mm−2) (Fig. 6). No differences between the two
Table 3 Morphometric data of lymphatic and blood vessels
Lymphatic vessels Blood vessels
Papillary Reticular Papillary Reticular
Vessel density a Controls 18.1 ± 5.3 8.9 ± 1.2 139.5 ± 39 36.4 ± 6.7
Ssc 8.4 ± 3.7 4.9 ± 1.1 ⁎ 113.6 ± 29.7 35.7 ± 4.6
Percentage vessel area b Controls 0.3 ± 0.1 0.4 ± 0.1 4.4 ± 0.9 2.2 ± 0.4
Ssc 0.1 ± 0.1 0.2 ± 0.04 ⁎ 2.6 ± 0.5 2.1 ± 0.4
Mean vessel area c Controls 186 ± 53 511 ± 114 347 ± 58 657 ± 112
Ssc 290 ± 347 490 ± 111 263 ± 28 597 ± 85
Mean percentage luminal area d Controls 14.7 ± 6.8 15.9 ± 3.9 7.9 ± 1.6 11 ± 0.5
Ssc 15.6 ± 11.9 24 ± 4.9 ⁎ 12.6 ± 1.1 12.7 ± 1.1
Ellipse shape factor Controls 0.21 ± 0.03 0.17 ± 0.02 0.5 ± 0.02 0.51 ± 0.01
Ssc 0.3 ± 0.04 0.22 ± 0.02 0.48 ± 0.02 0.47 ± 0.01
Roundness Controls 0.39 ± 0.06 0.32 ± 0.03 0.77 ± 0.02 0.77 ± 0.01
Ssc 0.47 ± 0.09 0.4 ± 0.03 0.75 ± 0.02 0.73 ± 0.01
% Profiles Controls 41.3 ± 15.6 32.9 ± 8.1 19.9 ± 6.2 7.9 ± 2.6
Ssc 56.3 ± 12.8 27.5 ± 8.6 5.2 ± 3.2 ⁎ 3.0 ± 1.4 ⁎
a Vessels/mm2.
b Total vessel area/total tissue area × 100.
c μm2.
d Luminal area/vessel area × 100.
⁎ P b .05 versus controls.
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among blood vessels.
To assess whether periglandular lymphatic vessel preser-
vation could be due to local production of lymphangiogenic
factors, some sections were stained with a polyclonal
antibody to VEGF-C. The epithelial cells of glands were
strongly immunoreactive for VEGF-C (Fig. 7). As expected,
lymphatic endothelium was also immunoreactive for VEGF-
C (data not shown).Fig. 3 Distribution of lymphatic vessels in relation to their
individual area (outer vessel area in μ2) does not differ in SSc
versus controls.4. Discussion
While the role of blood vessel and vessel dysfunction in
the pathogenesis of SSc has been the object of much
investigation, only a microlymphography study by Leu et al.
[22] focuses on lymphatic vessels in this disease. The present
immunohistochemical study is, to the best of our knowledge,
the first detailed expression and morphometric analysis of
lymphatic vessels in the skin of patients affected by SSc.Fig. 4 Distribution of the percentage of dilation of lymphatic vessels
evaluated as inner luminal area in relation to total area. Increased
percentage of vessels with dilated lumen in SSc versus controls.
Fig. 5 The lymphatic vessels (arrows) around sebaceous (A) and
sweat (B) glands are preserved in SSc patients. Original
magnification ×20.
Fig. 6 Box plot graph of the density of periglandular and not
periglandular lymphatic vessels of reticular dermis in SSc patients
compared with controls. In SSc patients there is a significant (P =
.02) reduction of not periglandular lymphatic vessels; whereas
periglandular lymphatic vessels are preserved. The line in the box
represents the median, the box margins the upper and lower
quartiles, and the whiskers the range.
Fig. 7 The epithelium of sweat glands is strongly immunoreac-
tive for VEGF-C. Original magnification ×20.
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control skin: the epidermis thickness increased with duration
of disease. Loss of dermal-epidermal ridges and flattening of
papillae with effacement of rete reminded of the changes that
has been described in aging skin in association with failure of
vasculature [25].
A marked, significant decrease of lymphatic vessel
number and an increase in the inner luminal area (implying
dilation) of the remaining ones was observed in the reticular
dermis of SSc patients compared with controls. A similar
trend was seen in the papillary layer, possibly failing to reach
statistical significance only because of the reduced statistical
power, due to the relatively smaller area of the papillary as
compared to the reticular dermis. Dilation of lymphatic
vessels may be interpreted as a compensatory mechanism for
the reduction in their number. Since skin lymphatic vessel
are usually collapsed, the increased percentage of dilated
lymphatic vessels may also indicate the presence of a certain
degree of lymphostasis. Dilation of lymphatic vessels has
been sporadically reported in other autoimmune diseases: in
the skin in cutaneous histiocytic lymphangitis, an unusual
manifestation of rheumatoid arthritis [26,27] and in theintestine in a case of protein losing enteropathy in systemic
lupus erythematosus [28].
In contrast with the decrease in density of reticular dermis
lymphatic vessels, we found that periglandular lymphatics
are well preserved and dilated in the skin of SSc patients,
suggesting that the microenvironment in the proximity of the
glands is somewhat protective for lymphatics. The glands
and the other skin appendages have been shown to be
preserved, although reduced in number, even in the advanced
skin pattern of the disease [29]. VEGF-C is expressed in the
immature cells of sebaceous glands in an animal model of
cutaneous wound healing [19]. In this study, we report that
sweat glands are also positive for the lymphatic specific
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hypothesize that local production of angiogenic factors by
sweat and sebaceous glands may be responsible for
periglandular lymphatic preservation.
Unlike others [1], we failed to detect significant
differences in the density of blood vessels between SSc
and controls. This could be explained by differences in the
patient population or in the methods used. Notably, Fleming
et al [30] did not report separate data for papillary and
reticular dermis, while we found that vessel density is very
different in these regions. It is plausible that Fleming's data
were biased by an imbalance in the percentage of papillary
and reticular tissue present in the biopsies of the two groups
that they examined. Nevertheless, we confirm their finding
that the number of “profiles” (blood vessels without a visible
lumen) is reduced in SSc.
Whatever the cause of the discrepancy with previous data,
our data indicate that the lymphatic microcirculation is
altered earlier and more consistently than its blood
counterpart. It is difficult to speculate on the possible
mechanisms of this phenomenon. Extensive studies on blood
vessels in scleroderma suggests that vascular loss is due to a
combination of vessel destruction by a variety of mechan-
isms [31], including defective angiogenesis [32], defective
vasculogenesis (a reduction in number, and function of
circulating endothelial stem cells has been found in SSc
patients) [33-35], and auto-antibodies (particularly antien-
dothelial cell antibodies, which are commonly found in SSc
patients) [31]. It is unknown whether the same antibodies
may also act on lymphatic endothelium and/or whether
autoantibodies specific for lymphatic endothelium exist.
Although no information is available about lymphatic
vessels in SSc, all these mechanisms could be involved in
the decrease in lymphatic vessel density. Lymphatic vessels
could be more sensitive to damage than blood vessels
because of the more fragile structure of their wall [36], which
is made by a thin layer of endothelial cells without smooth
muscle cells or pericytes. As for angiogenesis, studies in the
last decade have led to a better understanding of the cell and
molecular mechanisms involved, showing that lymphangio-
genesis and angiogenesis are partially characterized by a
distinctive dependence from different ligands and receptors.
Thus, angiogenesis is mostly dependent on the linkage of
VEGF-A and B on receptors VEGF receptor-1 and VEGF
receptor-2, while lymphangiogenesis is more dependent on
VEGF-C and D binding to VEGF receptor-3 [13,37]. VEGF
and VEGF receptors are by no means the only molecules
involved, and many more have been identified. While several
studies in SSc have investigated a variety of molecules
involved in angiogenesis, sometimes with conflicting results
(reviewed in Refs. [1,31,32]), much less information is
available about mediators of lymphangiogenesis, and there
are currently no data to support or explain a defect in
lymphangiogenesis in these patients. In fact, both circulating
levels of VEGF-C [38] and local expression of its lymphatic
receptor VEGF receptor-3 in the skin [39] have been reportedto be increased in patients with scleroderma, and no data are
available on other molecules potentially involved. Bone-
marrow-derived circulating endothelial precursors are
thought to be recruited for the formation and repair of
blood vessels in adults [40] and have also been found in
newly formed lymphatic vessels in a corneal lymphangio-
genesis model in mice [41]. Bone-marrow-derived circulat-
ing endothelial precursors are significantly reduced in the
serum of SSc compared to rheumatoid arthritis patients and
healthy subjects [33,34], but no data are yet available on
circulating lymphatic endothelial precursors in these
patients. Much more data are needed to investigate the
distribution of a larger spectrum of molecules involved in
lymphangiogenesis in scleroderma and to elucidate whether
the reported overexpression of VEGF-C and VEGF receptor-
3 despite apparent decrease in lymphatics constitutes an
exaggerated response to a block of lymphangiogenesis in
some downstream mechanism, such as a defect in circulating
lymphatic precursors. Furthermore, it would be important to
investigate whether lymphangiogenesis occurs in earlier
stages of the disease.
Regardless of the mechanism and the timing, the
disappearance of lymphatic vessels could have a pathogenic
role in the evolution of the disease. Once lymphatic vessels
are damaged and are no longer functional, fluids and
macromolecules derived from blood microvessels may
accumulate in the interstitial fluid causing edema at first
and subsequently fibrosis. This is frequently observed in SSc
patients in which an early edematous phase is followed with
time by progressive fibrosis. Indeed, we found that the lumen
of the lymphatic vessels was enlarged with respect to
controls, suggesting that these vessels are relatively over-
loaded, possibly as a result of an increase in interstitial fluid
due to the pathologic process and/or to the overall reduced
capacity of lymph drainage caused by the decreased number
of vessels.
In conclusion, we showed, for the first time, that
lymphatic vessels are markedly affected in the skin lesions
of scleroderma. This observation could lead to a better
understanding of the pathogenic mechanisms of the early
phases of the disease process, and open new avenues for
therapeutic advantage.References
[1] Fleming JN, Schwartz SM. The pathology of scleroderma vascular
disease. Rheum Dis Clin North Am 2008;34:41-55.
[2] Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem
fibrotic disorder. J Clin Invest 2007;117:557-67.
[3] Claman HN, Giorno RC, Seibold JR. Endothelial and fibroblastic
activation in scleroderma. The myth of the “uninvolved skin”. Arthritis
Rheum 1991;34:1495-501.
[4] LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis
Clin North Am 1996;22:675-94.
[5] Abraham D, Distler O. How does endothelial cell injury start? The role
of endothelin in systemic sclerosis. Arthritis Res Ther 2007;9:S2.
374 A. Rossi et al.[6] Kallenberg CG. Early detection of connective tissue disease in patients
withRaynaud's phenomenon. RheumDisClinNorthAm1990;16:11-30.
[7] Cutolo M, Pizzorni C, Tuccio M, et al. Nailfold videocapillaroscopic
patterns and serum autoantibodies in systemic sclerosis. Rheumatol-
ogy 2004;43:719-26.
[8] Distler O, Distler JH, Scheid A, et al. Uncontrolled expression of
vascular endothelial growth factor and its receptors leads to
insufficient skin angiogenesis in patients with systemic sclerosis.
Circ Res 2004;95:109-16.
[9] Choi JJ, Min DJ, Cho ML, et al. Elevated vascular endothelial growth
factor in Systemic Sclerosis. J Rheumatol 2003;30:1529-33.
[10] Distler O, Del Rosso A, Giacomelli R, et al. Angiogenic and
angiostatic factors in systemic sclerosis: increased levels of vascular
endothelial growth factor are a feature of the earliest disease stages and
are associated with the absence of fingertip ulcers. Arthritis Res
2002;4:R11.
[11] Dor Y, Djonov V, Abramovitch R, et al. Conditional switching of
VEGF provides new insights into adult neovascularization and pro-
angiogenic therapy. EMBO J 2002;21:1939-47.
[12] Kahaleh B, Meyer O, Scorza R. Assessment of vascular involvement.
Clin Exp Rheumatol 2003;21:S9-S14.
[13] Cueni LN, Detmar M. New insights into the molecular control of the
lymphatic vascular system and its role in disease. J Invest Dermatol
2006;126:2167-77.
[14] Jackowski S, Janusch M, Fiedler E, et al. Radiogenic lymphangiogen-
esis in the skin. Am J Pathol 2007;171:338-48.
[15] Kajiya K, Kunstfeld R, Detmar M, Chung JH. Reduction of lymphatic
vessels in photodamaged human skin. J Dermatol Sci 2007;47:241-3.
[16] Kahn HJ, Marks AA. new monoclonal antibody, D2-40, for detection
of lymphatic invasion in primary tumors. Lab Invest 2002;82:1255-7.
[17] Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar
M. Up-regulation of the lymphatic marker podoplanin, a mucin-type
transmembrane glycoprotein, in human squamous cell carcinomas and
germ cell tumors. Am J Pathol 2005;166:913-21.
[18] Kunstfeld R, Hirakawa S, Hong YK, et al. Induction of cutaneous
delayed-type hypersensitivity reactions in VEGF-A transgenic mice
results in chronic skin inflammation associated with persistent
lymphatic hyperplasia. Blood 2004;104:1048-57.
[19] Ji RC, Miura M, Qu P, Kato S. Expression of VEGFR-3 and 5′-Nase in
regenerating lymphatic vessels of the cutaneous wound healing.
Microsc Res Tech 2004;64:279-86.
[20] Oka M, Iwata C, Suzuki HI, et al. Inhibition of endogenous TGF-beta
signaling enhances lymphangiogenesis. Blood 2008;111:4571-9.
[21] Clavin NW, Avraham T, Fernandez J, et al. TGF-beta1 is a negative
regulator of lymphatic regeneration during wound repair. Am J Physiol
Heart Circ Physiol 2008;295:H2113-27.
[22] Leu AJ, Gretener SB, Enderlin S, et al. Lymphatic microangiopathy of
the skin in systemic sclerosis. Rheumatology (Oxford) 1999;38:221-7.
[23] LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic
sclerosis) classification, subsets and pathogenesis. J Rheumatol 1988;15:
202-5.[24] West BT, Welch BT, Gatecki AT, editors. Linear mixed models. A
practical guide using statistical software. Boca Raton (Fla): Chapman
and Hall/CRC; 2007. p. 353.
[25] Ryan T. The ageing of the blood supply and the lymphatic drainage of
the skin. Micron 2004;35:161-71.
[26] Pruim B, Strutton G, Congdon S, Whitehead K, Donaldson E.
Cutaneous histiocytic lymphangitis: an unusual manifestation of
rheumatoid arthritis. Australas J Dermatol 2000;41:101-5.
[27] Takiwaki H, Adachi A, Kohno H, Ogawa Y. Intravascular or
intralymphatic histiocytosis associated with rheumatoid arthritis: a
report of 4 cases. J Am Acad Dermatol 2004;50:585-90.
[28] Tanaka T, Damião AO, Gabriel Júnior A, et al. Protein-losing
enteropathy in systemic lupus erythematosus. Rev Hosp Clin Fac Med
Sao Paulo 1991;46:34-7.
[29] Ibba-Manneschi L, Niissalo S, Milia AF, et al. Variation of neuronal
nitric oxide synthase in systemic sclerosis skin. Arthritis Rheum
2006;54:202-13.
[30] Fleming JN, Nash RA, McLeod DO, et al. Capillary regeneration in
scleroderma: stem cell therapy reverses phenotype? PLoS ONE 2008;
e1452:3.
[31] Kahaleh B. Vascular disease in scleroderma: mechanisms of vascular
injury. Rheum Dis Clin North Am 2008;34:57-71.
[32] Mulligan-Kehoe MJ, Simons M. Vascular disease in scleroderma:
angiogenesis and vascular repair. Rheum Dis Clin North Am 2008;34:
73-9.
[33] Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Defective
vasculogenesis in systemic sclerosis. Lancet 2004;364:603-10.
[34] Del Papa N, Quirici N, Soligo D, et al. Bone marrow endothelial
progenitors are defective in systemic sclerosis. Arthritis Rheum
2006;54:2605-15.
[35] Gomer RH. Circulating progenitor cells and scleroderma. Curr
Rheumatol Rep 2008;10:183-8.
[36] Ryan TJ. Structure and functions of lymphatics. J Invest Dermatol
1989;93:18S-24S.
[37] Adams RH, Alitalo K. Molecular regulation of angiogenesis and
lymphangiogenesis. Nat Rev Mol Cell Biol 2007;8:464-78.
[38] Chitale S, Al-Mowallad AF, Wang Q, Kumar S, Herrick A.
High circulating levels of VEGF-C suggest abnormal lymphan-
giogenesis in systemic sclerosis. Rheumatology (Oxford) 2008;47:
1727-8.
[39] Mackiewicz Z, Sukura A, Povilenaité D, et al. Increased but
imbalanced expression of VEGF and its receptors has no positive
effect on angiogenesis in systemic sclerosis skin. Clin Exp Rheumatol
2002;20:641-6.
[40] Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of
endothelial progenitor cells responsible for postnatal vasculogenesis in
physiological and pathological neovascularization. Circ Res 1999;85:
221-8.
[41] Religa P, Cao R, Bjorndahl M, et al. Presence of bone marrow-derived
circulating progenitor endothelial cells in the newly formed lymphatic
vessels. Blood 2005;106:4184-90.
